CD274 and neoplasm: It has been shown that there is a positive correlation between the number of inflammatory cells that infiltrate the tumor and the response to anti-PD-1/PD-L1 drugs, such as Nivolumab: indeed, the immunoinflammatory phenotype is the one that mostly responds to immunotherapy [24].